[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6214 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. R. 6214
To amend title XVIII of the Social Security Act to improve access to
innovative treatment options for end-stage renal disease under the
Medicare program, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
November 20, 2025
Mrs. Miller of West Virginia (for herself and Ms. Sewell) introduced
the following bill; which was referred to the Committee on Ways and
Means, and in addition to the Committee on Energy and Commerce, for a
period to be subsequently determined by the Speaker, in each case for
consideration of such provisions as fall within the jurisdiction of the
committee concerned
_______________________________________________________________________
A BILL
To amend title XVIII of the Social Security Act to improve access to
innovative treatment options for end-stage renal disease under the
Medicare program, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,

6ac8d368ba61f99993ad77646025741fec8267c4f33e4327e34f9b09972813b8

(a) In General.--This Act may be cited as the ``Kidney Care Access
Protection Act''.
(b) Table of Contents.--The table of contents of this Act is as
follows:

58eb266b5963a8660577fb90c784741ef17ea7080591339331f9d8a340189b18

improve access to innovative treatment
options.

8cdb16b8646e0ee0781a4f021f459777f3651669cd491115b56e932a7d40b98d

TITLE I

-PROTECTING PATIENT ACCESS TO KIDNEY CARE INNOVATION

648073d91d3a403383215211015cf4d9f24d305e762c699d95edb954c67578a0

25c3308bcdc49ca36826fbe41a38f8525335489864ea299cca7f2090e0670b5c

TITLE II

-ADDRESSING STAFFING BARRIERS WITH ESRD MARKET BASKET LABOR

4686933c5017e419fe85a89193f8db570e4761294d1a8c7addc0b88488230da8

TITLE III

-PREVENTING KIDNEY DISEASE AND EXPANDING AWARENESS AND

dcbd9f6cc1c84ea85ecb672def5d049321f2ce4e1140e7a8fdcdb66073b16a52

IMPROVE ACCESS TO INNOVATIVE TREATMENT OPTIONS.
(a) Extension of Transitional Drug Add-On Payment Adjustment
(TDAPA) Period.--The Secretary of Health and Human Services (in this
section referred to as the ``Secretary'') shall pay the transitional
drug add-on payment adjustment under section 413.234(c) of title 42,
Code of Federal Regulations (or a successor regulation), for not less
than 3 years for any new renal dialysis drug or biological product--
(1) approved by the Food and Drug Administration on or
after January 1, 2020, under section 505 of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 355) or section 351 of the
Public Health Service Act (42 U.S.C. 262);
(2) that qualifies for such adjustment under such section;
and
(3) that is furnished on or after January 1, 2026.
(b) Permanent Post-TDAPA Adjustment.--Section 1881(b)(14) of the
Social Security Act (42 U.S.C. 1395rr(b)(14)) is amended by adding at
the end the following new subparagraph:
``(J) Payment for new and innovative drugs, biologicals,
and devices that are renal dialysis services.--
``(i) In general.--For any new renal dialysis drug
or biological product that is used to treat or manage a
condition as defined in section 413.234(a) of title 42,
Code of Federal Regulations that received a
transitional drug add-on payment adjustment (referred
to in this subparagraph as `TDAPA') under section
413.234(c) of such title, and was furnished on or after
January 1, 2024, the Secretary shall establish a
permanent add-on adjustment to the base rate for claims
submitted on or after January 1, 2026, that includes
the administration of such drugs or biologicals.
``(ii) Calculation of the post-tdapa add-on
adjustment.--In calculating the add-on adjustment
described in clause (i), the Secretary shall--
``(I) base the calculation on--
``(aa) except as provided in items
(bb) and (cc), the most recent 12-month
period of utilization for the new renal
dialysis drug or biological product and
the most recent available full calendar
quarter of average sales price data for
such drug or product;
``(bb) if the most recent available
full calendar quarter of average sales
price data reflects 0 or negative
sales, 100 percent of the wholesale
acquisition cost (as defined in section
1847A(c)(6)) of such drug or product;
or
``(cc) if the wholesale acquisition
cost is not available, the drug
manufacturer's invoice;
``(II) calculate the post-TDAPA add-on
payment adjustment as the expenditures for the
new renal dialysis drug or biological product
divided by the total number of renal dialysis
services during which such drug or biological
was administered during the same period;
``(III) set the amount of the add-on
adjustment as an amount equal to 65 percent of
the amount calculated under subclause (II);
``(IV) update the add-on adjustment
annually to account for inflationary changes;
and
``(V) apply the add-on adjustment amount
immediately upon the expiration of the TDAPA
period and availability of the post-TDAPA add-
on adjustment.
``(iii) Implementation.--This subparagraph shall
not be implemented in a budget neutral manner and shall
not be adjusted by any applicable patient-level case-
mix adjustments described in section 413.235 of title
42, Code of Federal Regulations (or any successor
regulation).''.
(c) Clarification to Definition of Renal Dialysis Services.--
Section 1881(b)(14)(B) of the Social Security Act (42 U.S.C.
1395rr(b)(14)(B)) is amended--
(1) by redesignating clauses (i) through (iv) as subclauses
(I) through (IV), respectively;
(2) by inserting ``(i)'' after ``(B)'';
(3) in clause (i)(IV), as added by paragraph (2), by
striking ``clause (i)'' and inserting ``subclause (I)'';
(4) in the flush text at the end, by striking ``Such term
does not'' and inserting the following:
``(ii) Such term--
``(I) does not'';
(5) in clause (ii), as added by paragraph (2)--
(A) in subclause (I), by striking the period at the
end and inserting ``; and''; and
(B) by adding at the end the following:
``(II) does not include drugs or biological products used
to treat a comorbid disease or condition (including
cardiovascular disease, an inflammatory condition, cancer,
diabetes, and obesity) that may occur in an individual who has
been determined to have end-stage renal diseases and is
receiving dialysis and--
``(aa) that have been approved by the Food
and Drug Administration after December 31,
2025; and
``(bb) do not substitute for a drug or
biological included in the ESRD prospective
payment system base rate.''; and
(6) by adding at the end the following new clause:
``(iii) Implementation.--Beginning on the date of enactment
of this clause, for purposes of implementing clause (ii)(II),
the Secretary shall require that a claim for a drug or
biological product described in such clause, that is payable
under this part and is furnished by a provider of services or
renal dialysis facility, contain the AY modifier (or a
successor modifier).''.
(d) Revisions to Transitional Add-On Payment Adjustment for New and
Innovative Equipment and Supplies (TPNIES).--
(1) Extension of period.--The Secretary shall pay the
transitional add-on payment adjustment for new and innovative
equipment and supplies under section 413.236 of title 42, Code
of Federal Regulations (or a successor regulation), for not
less than 3 years for any new renal dialysis device that--
(A) qualifies for such adjustment; and
(B) is furnished on or after January 1, 2026.
(2) Eligibility of breakthrough devices.--Beginning January
1, 2026, a device designated for expedited development and
priority review under section 515B of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. 360e-3) shall be eligible for a
transitional add-on payment adjustment for new and innovative
equipment and supplies under section 413.236 of title 42, Code
of Federal Regulations (or a successor regulation).
(3) Inclusion of capital-related assets in the transitional
add-on payment adjustment for new and innovative equipment and
supplies and post-transitional add-on payment adjustment for
new and innovative equipment and supplies.--Beginning January
1, 2026, the Secretary shall not apply the criterion described
in section 413.236(b)(6) of title 42, Code of Federal
Regulations (or a successor regulation), that excludes capital-
related assets from the transitional add-on payment adjustment
for new and innovative equipment and supplies and shall
calculate such adjustment for capital-related assets that are
devices that otherwise meet the requirements for the
transitional add-on payment adjustment for new and innovative
equipment.
(e) Effective Date.--The amendments made by this section shall take
effect on January 1, 2026, and apply to items and services furnished on
or after such date.

50baa5f1724ba99835930a05a9518dc3e2a61cdef14cdfa1e706469155af495f

THERAPIES.
(a) In General.--Section 1853(c) of the Social Security Act (42
U.S.C. 1395w-23(c)) is amended by adding at the end the following new
paragraph:
``(8) Treatment of innovative products for enrollees with
end stage renal disease.--
``(A) In general.--Beginning January 1, 2026, the
Secretary shall make direct payment adjustments to
providers of services or renal dialysis facilities
for--
``(i) any new renal dialysis drug or
biological product that receives a transitional
drug add-on payment adjustment under section
413.234(c) of title 42, Code of Federal
Regulations; or
``(ii) an item or service that receives a
transitional add-on payment adjustment for new
and innovative equipment and supplies under
section 413.236 of such title.
``(B) Amount of direct payment.--The amount of the
adjustment shall equal the amount determined under the
end-stage renal disease prospective payment system
described in section 1881(b)(14).
``(C) Duration of direct payment.--The Secretary
shall make payments under subparagraph (A) for the
duration of the transitional payment under the end-
stage renal disease prospective payment system
described in such section.''.
(b) Conforming Amendments.--Section 1851(i) of the Social Security
Act (42 U.S.C. 1395w-21) is amended--
(1) in paragraph (1), by inserting ``1853(c)(8),'' after
``1886(h)(3)(D),''; and
(2) in paragraph (2), by inserting ``1853(c)(8),'' after
``1853(h),''.
ADJUSTMENTS

da5bb0ade6db5d29fdd64782983b05e439e48d409715aced238d96c48d9cb7d9

Section 1881(b)(14)(F)(i) of the Social Security Act (42 U.S.C.
1395rr(b)(14)(F)(i)) is amended--
(1) in subclause (I), by striking ``subclauses (II) and
(III)'' and inserting ``subclauses (II), (III), and (IV)'';
(2) in subclause (II), by inserting ``and after application
of subclause (IV)'' after ``subclause (I)''; and
(3) by adding at the end the following new subclause:
``(IV) Beginning with 2026, the Secretary
shall compute an adjustment to the increase
factor described in subclause (I) for the
annual update of the payment amounts
established under this paragraph for the
previous year to account for forecast error
(referred to in this subclause as the `forecast
error adjustment'). The initial adjustment (in
2026) to the increase factor shall take into
account the cumulative forecast error for 2021
and 2022. Subsequent adjustments in succeeding
years shall take into account the forecast
error from the most recently available year for
which there is final data. The forecast error
adjustment under this subclause shall apply
whenever the difference between the forecasted
and actual percentage change in the prices of
an appropriate mix of goods and services
included in renal dialysis services exceeds 0.5
percentage points.''.
EDUCATION

1639c299a2db350242ba9c22df00320ed73a2cf82b5666a029f46882d55e0f83

DISEASE SCREENING.
(a) In General.--Section 1861(ww)(2) of the Social Security Act (42
U.S.C. 1395x(ww)(2)) is amended--
(1) by redesignating subparagraph (O) as subparagraph (P);
and
(2) by inserting after subparagraph (N) the following new
subparagraph:
``(O) Chronic kidney disease screening as defined
by the Secretary.''.
(b) Effective Date.--The amendments made by this section shall
apply to items and services furnished on or after January 1, 2026.

88da77b96c47d0c32146ae9ec5b94d1471ce3068cc44f3f452e3ec725fc709fc

BENEFIT.
(a) In General.--Section 1861(ggg) of the Social Security Act (42
U.S.C. 1395x(ggg)) is amended--
(1) in paragraph (1)--
(A) in subparagraph (A), by inserting ``or stage
V'' after ``stage IV''; and
(B) in subparagraph (B), by inserting ``or of a
physician assistant, nurse practitioner, or clinical
nurse specialist (as defined in section 1861(aa)(5))
assisting in the treatment of the individual's kidney
condition'' after ``kidney condition''; and
(2) in paragraph (2)--
(A) by striking subparagraph (B); and
(B) in subparagraph (A)--
(i) by striking ``(A)'' after ``(2)'';
(ii) by striking ``and'' at the end of
clause (i);
(iii) by striking the period at the end of
clause (ii) and inserting ``; and'';
(iv) by redesignating clauses (i) and (ii)
as subparagraphs (A) and (B), respectively; and
(v) by adding at the end the following:
``(C) a renal dialysis facility subject to the
requirements of section 1881(b)(1) with personnel who--
``(i) provide the services described in
paragraph (1); and
``(ii) is a physician (as defined in
subsection (r)(1)) or a physician assistant,
nurse practitioner, or clinical nurse
specialist (as defined in subsection
(aa)(5)).''.
(b) Payment to Renal Dialysis Facilities.--Section 1881(b) of the
Social Security Act (42 U.S.C. 1395rr(b)) is amended by adding at the
end the following new paragraph:
``(15) For purposes of paragraph (14), the single payment for renal
dialysis services under such paragraph shall not take into account the
amount of payment for kidney disease education services (as defined in
section 1861(ggg)). Instead, payment for such services shall be made to
the renal dialysis facility on an assignment-related basis under
section 1848.''.
(c) Effective Date.--The amendments made by this section shall
apply to kidney disease education services furnished on or after
January 1, 2026.
<all>

d6aefa935a580df63da35502b5463bb37e0225c90743b1374f97250d0e8b38f9

Kidney Care Access Protection Act — HR. 6214

Other Sections

TITLE I

TITLE II

TITLE III

Want the full experience?